All articles by Abi Millar

Exploring the promise of billion-dollar KRAS drugs

In May 2021, when Amgen’s Lumakras (sotorasib) was launched, the milestone was met with great fanfare. Intended for certain patients…
Decoding the Covid-19 connection with diabetes

Early in the pandemic, it became clear that Covid-19 infection spelt trouble for people with diabetes. While not at greater…
The challenges of multiple drugs safety reporting

Polypharmacy – typically defined as taking five or more medications every day – has become a staple of many people’s…
Digitising the pharma supply chain

Since the start of the pandemic, the pharmaceutical supply chain has been under scrutiny. Never much of a talking point…
The ethics of vaccine boosters

As we head towards the winter, countries around the world are nervously eyeing their rates of Covid-19. If rates were…

Living medicines: using bacteria to fight cancer

In the late 19th century, an American bone surgeon named William Coley discovered a surprising pattern: cancer patients who also…
Five pharma cybersecurity breaches to know and learn from

At the start of the Covid-19 pandemic, digital adoption increased at a rate never seen before. With lockdowns and physical…
Ferring draws closer to a microbiome breakthrough

Clostridium difficile, also known as C. diff, often traps patients in a vicious cycle. A bacterial infection causing persistent diarrhoea…
Fighting India’s ‘black fungus’ epidemic

In May, just as the Delta variant of Covid-19 was ripping its way through India, we began to hear reports…
Blood plasma production: OK for the UK?

On 7 April, people in the UK were permitted to donate blood plasma for medicines for the first time in…